N06 Exploring predictors associated with Inflammatory Bowel Disease (IBD) helpline (HL) utilisation in a regression model: Crohn’s Colitis Cure Data Insights Program

Abstract Background HLs provide support, and proactive disease and remote medication management. Similarly, HLs provide nursing care and advice to IBD patients that serve to complement and enhance medical care. Herein, certain predictors such as patient demographics, treating site and disease and treatment characteristics regarding use of HL were explored, in a stepwise logistic regression model. Methods Crohn’s Colitis Care (CCCare), a cloud-based IBD-specific electronic medical record used in Australia and New Zealand, continuously feeds de-identified data into a clinical quality registry (CQR). Data prospectively entered from September 2023 to September 2024, from people with an assessment within 14 months, were retrospectively analysed. A stepwise logistic regression model to ascertain the odds of contacting HL among IBD patients was used. Results In a cohort of n = 2,357, from 5 different care sites, predictors such as treating site, surgery, disease duration (in years), and presence of abdominal pain, were significant. People from treating sites 1, 2, 3 and 4 were overall less likely to contact HL compared to those from care site 5 (treating site 1 AOR 0.010, P 0.001; treating site 2 AOR 0.008, P 0.001; treating site 3 AOR 0.041, P 0.001, and treating site 4 AOR 0.044, P 0.001). People who ever had surgery were more likely to seek advice from HL than those who never had surgery (AOR 1.424, 95% CI 1.164-1.742, P 0.001). People with longer duration of disease were less likely to contact HL than people with a short duration of disease (AOR 0.986, 95% CI 0.977-0.995, P = 0.002). Lastly, people with abdominal pain had a higher likelihood of contacting HL, compared to those without abdominal pain (AOR 1.678, 95% CI 1.342-2.098, P 0.001). Conclusion While HL use differed markedly by site, other shared patient factors predicted use across treating site; with ever having surgery and abdominal pain increasing use, whilst treating site and longer duration of disease decreased use. These results from this exploratory study will serve to better inform factors relevant to the provision of proactive patient care – not only to enhance HL services, but also to pre-empt the need for HL use by earlier provision of relevant information and/or care. Conflict of interest: Rivas, Consuelo: No conflict of interest Su, Wai Kin: No conflict of interest Davidson, Chloe: No conflict of interest Wu, Rodger: No conflict of interest Wilson, William: No conflict of interest Andrews, Jane Mary: The work I will present was funded via CCCure. CCCure’s funding sources include grants for research and payments for data reports from Pharma including AbbVie, J&J, Takeda, Celltrion, Falk, Ferring, BMS, Janssen, Pfizer, Sandoz Connor, Susan Jane: Grant: Research Support: Abbvie, Agency for Clinical Innovation, Amgen, BMS, Chiesi, Celltrion, DrFalk, Ferring, Janssen, Medical Research Future Fund, Pfizer, South Western Sydney Local Health District, Sydney Partnership for Health, Research and Enterprise, Takeda and The Leona M and Harry B Helmsley Charitable Trust Personal Fees: Ad Boards: Abbvie, Amgen, BMS, Celltrion, Eli Lilly, Ferring, GSK, Janssen, Organon, Pfizer, Takeda Speaker Fees: Abbvie, Cornerstones Health, Dr Falk, Ferring, Janssen, Pfizer, Sandoz, Sydney IBD School, Takeda Educational Support: DrFalk, Sandoz, Takeda